At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo +1 moredrug
Likely dose
minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebofrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia: a Double-blind, Randomized, Crossover Pilot Study
In Brief
A Phase 2 clinical trial evaluating minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo and Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily) for Fibromyalgia. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Evaluation of the effect of combinatorial treatment of fibromyalgia patients (standard of care + minocycline + N-acetylcysteine (NAC) relative to standard of care on subjective pain measurement Revised Fibromyalgia Impact Questionnaire (FIQR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFibromyalgia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2021
Primary CompletionAug 2022
TodayJul 2026
First PostedOct 20, 2020
Enrollment StartDec 6, 2021
Primary CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.7 years ago
Interventions
minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebodrug
minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)drug
Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)